This is the question I–along with co-authors Syvart Dennen, Priti Pednekar , Kelly Birch, Menaka Bhor, Julie Kanter , and Peter Neumann–aim to answer in our new paper in JMCP. The full title is: “For which diseases do broader value elements matter most? An evaluation… Read More »For which diseases do broader value elements matter most?
In its report released last Tuesday, a nonprofit drug pricing research group claims that seven drugs have prices that do not align with any newly discovered increase in clinical benefit, leading to over $1.2 billion in excess drug spending in 2019, alone.
US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and concluded that seven of those were not backed by any clinical evidence. The cost to the American taxpayer from those increases? Around $1.2 billion for the seven… Read More »Amgen’s Enbrel heads ICER list of unjustified US price rises
Check out my interview on the Redeeming Value podcast with Brian Reid. PRECISIONheor Vice President Jason Shafrin pops in to talk about the Institute of Clinical and Economic Review and the broader question of where the group’s influence is centered and the elements of ICER… Read More »Where — and Why — ICER Really Matters
COVID-19 is a global pandemic and finding a vaccine for COVID-19 would be a boon to societal. The value would be enormous. One study found that the value would be more than 1.1% of GDP. Since global GDP is $87.7 trillion, the value of a… Read More »What is the “reputational value” of developing a COVID vaccine?